Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBWTF NASDAQ:NRC OTCMKTS:SPHRY NASDAQ:SRNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBWTFCannabis Wheaton Income$0.13+0.1%$0.11$0.06▼$0.16$181.87M1.39838,776 shs273,084 shsNRCNational Research$20.81+1.3%$18.77$11.01▼$22.79$467.21M0.37164,318 shs235,465 shsSPHRYStarpharma$4.70$4.93$0.55▼$5.70$197.84M1.23703 shs700 shsSRNESorrento Therapeutics$0.00$0.00$0.00▼$0.10$551K0.17308,219 shs270,312 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBWTFCannabis Wheaton Income+0.08%+2.67%+21.39%+30.36%+111.83%NRCNational Research+1.31%+12.24%+8.78%+21.48%+23.57%SPHRYStarpharma0.00%-6.00%-1.22%+44.62%+718.39%SRNESorrento Therapeutics0.00%-9.09%+100.00%-58.33%-54.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBWTFCannabis Wheaton Income$0.13+0.1%$0.11$0.06▼$0.16$181.87M1.39838,776 shs273,084 shsNRCNational Research$20.81+1.3%$18.77$11.01▼$22.79$467.21M0.37164,318 shs235,465 shsSPHRYStarpharma$4.70$4.93$0.55▼$5.70$197.84M1.23703 shs700 shsSRNESorrento Therapeutics$0.00$0.00$0.00▼$0.10$551K0.17308,219 shs270,312 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBWTFCannabis Wheaton Income+0.08%+2.67%+21.39%+30.36%+111.83%NRCNational Research+1.31%+12.24%+8.78%+21.48%+23.57%SPHRYStarpharma0.00%-6.00%-1.22%+44.62%+718.39%SRNESorrento Therapeutics0.00%-9.09%+100.00%-58.33%-54.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBWTFCannabis Wheaton Income 0.00N/AN/AN/ANRCNational Research 2.50Moderate Buy$23.0010.52% UpsideSPHRYStarpharma 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SRNE, CBWTF, NRC, and SPHRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/22/2026NRCNational Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$23.005/29/2026NRCNational Research Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBWTFCannabis Wheaton Income$108.41M1.68$0.03 per share4.55$0.09 per share1.41NRCNational Research$137.39M3.45$1.27 per share16.33$0.62 per share33.56SPHRYStarpharma$3.18M62.21N/AN/A$0.29 per share16.21SRNESorrento Therapeutics$60.32M0.01N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBWTFCannabis Wheaton Income$29.96M$0.026.36N/AN/A20.99%19.84%12.26%N/ANRCNational Research$11.60M$0.3953.36N/AN/A6.52%122.73%14.18%7/27/2026 (Estimated)SPHRYStarpharma-$6.47MN/AN/AN/AN/AN/AN/AN/A8/26/2026 (Estimated)SRNESorrento Therapeutics-$572.84M-$0.43N/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)Latest SRNE, CBWTF, NRC, and SPHRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/28/2026Q1 2026NRCNational ResearchN/A$0.21N/A$0.14N/A$34.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCBWTFCannabis Wheaton IncomeN/AN/AN/AN/AN/ANRCNational Research$0.643.08%+19.88%164.10%N/ASPHRYStarpharmaN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ALatest SRNE, CBWTF, NRC, and SPHRY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2026NRCNational Researchquarterly$0.163.08%6/26/20266/26/20267/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBWTFCannabis Wheaton Income0.212.231.35NRCNational Research5.480.520.52SPHRYStarpharmaN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBWTFCannabis Wheaton IncomeN/ANRCNational Research47.26%SPHRYStarpharmaN/ASRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipCBWTFCannabis Wheaton Income4.60%NRCNational Research9.20%SPHRYStarpharmaN/ASRNESorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBWTFCannabis Wheaton Income3691.43 billion1.37 billionNot OptionableNRCNational Research49022.75 million20.65 millionOptionableSPHRYStarpharma4542.09 millionN/ANot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataSRNE, CBWTF, NRC, and SPHRY HeadlinesRecent News About These CompaniesSorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi CoastJanuary 5, 2026 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comSorrento Shareholders Lose Discovery Bid Over Judge RelationshipMarch 28, 2025 | news.bloomberglaw.comNScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comDSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel InfillsOctober 24, 2024 | newsfilecorp.comNSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Resources to Sell Three Newfoundland Properties to Gold HunterMay 29, 2024 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified PersonMay 8, 2024 | newsfilecorp.comNDSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh RailingMay 1, 2024 | newsfilecorp.comNSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)March 12, 2024 | news.bloomberglaw.comNJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento TherapeuticsFebruary 7, 2024 | pharmaphorum.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Mission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Generac’s AI Power Pivot Raises a Bigger Question About Data Center DemandBy Jeffrey Neal Johnson | June 4, 2026SRNE, CBWTF, NRC, and SPHRY Company DescriptionsCannabis Wheaton Income OTCMKTS:CBWTF$0.13 +0.00 (+0.08%) As of 06/26/2026 03:52 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.National Research NASDAQ:NRC$20.81 +0.27 (+1.31%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$20.81 0.00 (0.00%) As of 06/26/2026 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Starpharma OTCMKTS:SPHRY$4.70 0.00 (0.00%) As of 06/25/2026 03:11 PM EasternStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Sorrento Therapeutics NASDAQ:SRNE$0.0010 0.00 (0.00%) As of 06/26/2026 03:26 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
